JAC Advance Access originally published online on February 11, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 639-649
© 2003 The British Society for Antimicrobial Chemotherapy
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001
1 Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171-4603; 2 Focus Technologies, Franklin, TN 37064, USA; 3 Focus Technologies, Koninginneweg 11, 1217 KP Hilversum, The Netherlands
Received 27 August 2002; returned 3 December 2002; revised 17 December 2002; accepted 20 December 2002
Antibiotic resistance was prevalent in Gram-positive pathogens collected from 40 sites in 15 European countries during 2000–2001. Among Staphylococcus aureus, 27.3% of all isolates submitted were resistant to oxacillin and ranged from 0% of isolates from the Netherlands to 36.9% of isolates from Portugal. The overall prevalence of vancomycin-resistant Enterococcus faecium was 25.1%, with Italy submitting the largest percentage of resistant isolates (60.6%). For Streptococcus pneumoniae, 9.4% of all isolates collected were resistant to penicillin with variation by country from 0% in the Netherlands to 20.7% in Portugal. Multidrug resistance (MDR), defined as concurrent resistance to three or more antimicrobials of different chemical classes, was observed in 24.6% of S. aureus, 19.6% of E. faecium and 3.6% of S. pneumoniae. The directed spectrum agents daptomycin, linezolid and quinupristin–dalfopristin were active in vitro against all isolates regardless of their resistance to other agents. Daptomycin and quinupristin–dalfopristin (MIC90s 0.5 mg/L) were equally active against oxacillin-resistant S. aureus compared with linezolid (MIC90 2 mg/L). The activities of daptomycin, quinupristin–dalfopristin and linezolid were not affected by resistance to vancomycin in E. faecium (MIC90s of 4, 2 and 2 mg/L, respectively). Daptomycin was more active against penicillin-resistant S. pneumoniae (MIC90 0.25 mg/L) than was quinupristin–dalfopristin (MIC90 0.5 mg/L) or linezolid (MIC90 2 mg/L). Daptomycin was highly active against clinically important Gram-positive pathogens, including those that were multiply resistant to currently available agents. The results of this study provide a benchmark of the activity of daptomycin against contemporary European isolates and will serve as a baseline to monitor future changes in the susceptibility of these organisms to daptomycin.
Keywords: daptomycin, Gram-positive pathogens, multidrug-resistant
* Corresponding author. Tel: +1-703-480-2575; Fax: +1-703-480-2654; E-mail: jkarlowsky{at}focusanswers.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Bubalo, M. Y. Munar, G. Cherala, B. Hayes-Lattin, and R. Maziarz Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever Antimicrob. Agents Chemother., February 1, 2009; 53(2): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Attwood and K. L. LaPlante Telavancin: A novel lipoglycopeptide antimicrobial agent Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Falagas, K. P. Giannopoulou, F. Ntziora, and K. Z. Vardakas Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence J. Antimicrob. Chemother., July 1, 2007; 60(1): 7 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. French Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin J. Antimicrob. Chemother., December 1, 2006; 58(6): 1107 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Friedman, J. D. Alder, and J. A. Silverman Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2137 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Huang and M. J. Rybak Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function J. Antimicrob. Chemother., January 1, 2006; 57(1): 116 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schriever, C. Fernandez, K. A. Rodvold, and L. H. Danziger Daptomycin: A novel cyclic lipopeptide antimicrobial Am. J. Health Syst. Pharm., June 1, 2005; 62(11): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Steenbergen, J. Alder, G. M. Thorne, and F. P. Tally Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections J. Antimicrob. Chemother., March 1, 2005; 55(3): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Dvorchik and D. Damphousse The Pharmacokinetics of Daptomycin in Moderately Obese, Morbidly Obese, and Matched Nonobese Subjects J. Clin. Pharmacol., January 1, 2005; 45(1): 48 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Senneville, L. Legout, M. Valette, Y. Yazdanpanah, F. Giraud, E. Beltrand, G. Obert, L. Dubreuil, H. Migaud, and Y. Mouton Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study J. Antimicrob. Chemother., October 1, 2004; 54(4): 798 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dvorchik, R. D. Arbeit, J. Chung, S. Liu, W. Knebel, and H. Kastrissios Population Pharmacokinetics of Daptomycin Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2799 - 2807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dvorchik and D. Damphousse Single-Dose Pharmacokinetics of Daptomycin in Young and Geriatric Volunteers J. Clin. Pharmacol., June 1, 2004; 44(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Daptomycin Journal Watch Infectious Diseases, October 27, 2003; 2003(1027): 4 - 4. [Full Text]
|
|